Eric Marandett on Changes to the Law of Written Description in Managing Intellectual Property

Managing Intellectual Property

 | December 13, 2011

 | Eric Marandett

Eric Marandett and Kerry Flynn, vice president of intellectual property at Shire Pharmaceuticals, co-authored “Navigate Written Description Post-Ariad” in Managing Intellectual Property, a leading global resource for news and analysis of top stories affecting IP law.  They discuss the growing concern, particularly in the biotech and pharmaceutical industries, of how much disclosure is required to support patent claims in light of key changes to the law of written description.


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.